C2N Diagnostics

We’re getting ready for another important day at CTAD—researchers and clinicians have important new data to share about the Precivity™ line of blood tests. Madrid Marriott Auditorium Hotel & Convention Center is the location. Thursday, October 31 8:30 a.m. – 8:45 a.m. CEST LB7: Plasma p-tau217 and related CSF proteomic markers of pathological progression are slowed by p75NTR modulation: A Phase 2a trial of LM11A31 in Alzheimer’s disease 1:55 p.m. – 2:20 p.m. CEST Keynote 4: Fluid biomarkers in research, clinical trials, and clinical practice Poster session: Thursday October 31 – 7:15 a.m. to Friday, November 1 – 5:00 p.m CEST LP054 Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD)   P072 Diagnostic Performance of Plasma Alzheimer’s Disease Biomarkers for Predicting Amyloid/Tau/Neurodegeneration Let’s connect in person. Schedule a meeting with our team at this link: https://lnkd.in/gVMKRD4r #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024

C2N’s sessions at CTAD continue to attract attention as researchers share their latest findings about the Precivity™ line of blood tests. We encourage you to click this link to schedule a meeting with our team. https://lnkd.in/gVMKRD4r   All sessions and posters will be held at the Madrid Marriott Auditorium Hotel & Convention Center. Wednesday, October 30 5:25 p.m. – 5:40 p.m. CEST 0C18 – Blood biomarkers to detect Alzheimer’s disease in clinical practice — a cross-sectional study in primary and secondary care Poster session: Tuesday, October 29 – 3:00 p.m. to Wednesday, October 30 – 5:00 p.m. CEST P007 Using plasma pTau217 ratio to forecast longitudinal progression substantially increases the efficiency of AD clinical trials #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024

C2N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at CTAD. Join us in Madrid and be among the first to learn about exciting new data for the Precivity™ line of blood tests. We encourage you to click this link to schedule a meeting with our team. https://lnkd.in/gVMKRD4r   All sessions and posters will be held at the Madrid Marriott Auditorium Hotel & Convention Center. Eight sessions and five posters will offer novel insights relating to the Precivity™ blood tests. These presentations/posters include: Sessions on C2N's Test Data Tuesday, October 29 5:40 p.m. – 5:55 p.m. CEST 0C4 - Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD 6:10 p.m. – 6:50 p.m. CEST Late breaking Symposium 1 - The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial Poster session: Tuesday, October 29 – 3:00 p.m. to Wednesday, October 30 – 5:00 p.m. CEST P007 Using plasma pTau217 ratio to forecast longitudinal progression substantially increases the efficiency of AD clinical trials #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024

Joel Braunstein, MD, CEO of #C2N Diagnostics, presents at today’s ADDF Summit at CTAD on the Future of Alzheimer’s Biomarkers in Clinical Care and Research with other research luminaries Dr. Miia Kivipelto, Dr. Jeffrey Cummings, Dr. Suzanne Schindler, Dr. Charlotte Teunissen, Dr. Henrik Zetterberg, and Howard Fillit, MD. #Alzheimers #Alzheimersdisease #precisiomedicine #bloodtests #CTAD24 #ADDFSummit #biomarkers

C2N Diagnostics is excited to present at the inaugural Alzheimer's Drug Discovery Foundation Summit: Advancements in Novel Therapeutics and Combination Therapy on Monday, October 28, preceding #CTAD24. C2N CEO and co-founder Joel Braunstein, MD will be on the panel discussing the “Future of Alzheimer’s Biomarkers in Clinical Care and Research Panel.” C2N acknowledges the generous support from the Alzheimer’s Drug Discovery Foundation; the Summit is an invite-only, full-day meeting that brings together expert collaboration of #scientists from academia and biotech, #industry and #government, and other thought leaders. The symposium will explore cutting-edge science that will accelerate the development of new treatments — guided by the #BiologyOfAging — and advance the field of Alzheimer's disease with innovative approaches around #CombinationTherapy and #PrecisionMedicine. Visit the website to learn more: https://lnkd.in/eSu8EWqr #AlzheimersDrugDiscoveryFoundation #ADDFSummit

The Washington Post reported on a study published in the JAMA, Journal of the American Medical Association about the effectiveness of the PrecivityAD2 blood test, which helps healthcare providers diagnose #Alzheimer’s disease. The research found that PrecivityAD2 test delivered a highly statistically significant accuracy of over 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis. Joel Braunstein, MD, C2N’s CEO and co-founder, says, “This landmark research shows how our consistent, robust, and high-performing blood tests are providing a clear picture of Alzheimer's disease pathology. The test performed the same in primary care and specialty memory care, and it was highly accurate regardless of patients’ clinical presentation and medical comorbidities.” https://lnkd.in/eJtbA6tC #WashingtonPost #research #precisionmedicine #C2NDiagnostics #PrecivityAD2

C2N Diagnostics and its partner Unilabs are proud to be part of the Alzheimer Europe's 2024 Conference in Geneva.  Daniel Connell (C2N), Marc Rojas (Unilabs), and Joni Henderson (C2N) congratulate Jean Georges and his team at Alzheimer Europe for a tremendous conference bringing together patients, caregivers, advocates, clinicians, researchers, and government leaders to further advancements in the care and treatment of those living with cognitive impairment.   #AlzheimerEurope #Unilab #34AEC #alzheimersdisease #alzheimers

Big news in the #Alzheimer’s world: New funding will help C2N Diagnostics in its work to advance blood tests for detecting tau tangle pathology. The $15 million GHR Foundation investment will support C2N in developing blood tests that will focus on a combination of tau-based blood biomarkers, including MTBR-tau, all of which are important indicators of pathological tau tangles and neurites associated with Alzheimer’s disease. These blood biomarkers will be integral to the accurate biological diagnosis of Alzheimer’s disease, staging the disease, and facilitating development of tau-directed therapeutics. C2N’s CEO, Dr. Joel Braunstein, says, “GHR’s vital support will continue to fuel our position as leaders in blood biomarker innovation and quality in the Alzheimer’s disease diagnosis space. The key beneficiaries of this C2N-GHR collaboration are the patients, families, and loved ones affected by the wrath of Alzheimer’s disease, which is only growing in prevalence.” https://lnkd.in/eFMEs2wp #investment #liquidbiopsy #GHRFoundation #Alzheimersdisease #dementia #funding #bloodtests #tautangles #MTBRtau #bloodbiomarkers

The ADDF is pleased to announce a new investment in C2N Diagnostics! This $7 million investment is the largest to-date from the ADDF’s Diagnostics Accelerator (DxA) and underscores the DxA’s commitment to developing and deploying #novel biomarkers, including blood tests, that will transform the #Alzheimers diagnostic landscape, a core tenet of the ADDF’s mission. C2N’s pioneering #BloodTests are rooted in scientific rigor with a history of breakthroughs. Notably, the company’s PrecivityAD® blood test was first-to-market with the help of ADDF seed-funding. With this new investment, C2N intends to develop a deployable version of its blood biomarker detection platform that will enable global access to the test. #Scalable, #accessible blood-based biomarkers will be critical accelerating drug development and clinical trials, as well as enabling a #CombinationTherapy and #PrecisionMedicine approach in Alzheimer’s, like in cancer care. Learn more about the investment here: https://bit.ly/3TGx8yu Mark Roithmayr Howard Fillit, MD Niranjan Bose Joel Braunstein, MD Joni Henderson

Together, we’re making big strides in Alzheimer’s disease diagnosis. Diagnostics Accelerator has awarded C2N up to $7.025 million in funding to develop a decentralized clinical mass spectrometry solution to enable high-performance Alzheimer’s disease testing worldwide The accessible, accurate, scalable, and standardized C2N Precivity™ testing strategy aligns with the vision of the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator. C2N CEO Joel Braunstein, MD says, “Early and accurate detection represents the greatest chance for transforming the trajectory of Alzheimer’s disease through early treatment and prevention. We thank the Diagnostics Accelerator for their trust and confidence in our approach. This project aims to truly redefine what it means to offer high-performance Alzheimer’s disease testing locally on a global scale.” https://lnkd.in/efyKcrN7 #investment #liquidbiopsy #ADDF #AlzheimersDrugDiscoveryFoundation